IQVIA Holdings Inc. Common Stock vs Weyerhaeuser Company Common Stock — how do they compare? IQVIA Holdings Inc. Common Stock trades at $265 (market cap $42.91B), while Weyerhaeuser Company Common Stock trades at $19.04 (market cap $13.67B). The key difference: IQVIA Holdings Inc. Common Stock is far larger — about 3.1× Weyerhaeuser Company Common Stock's market cap, and Weyerhaeuser Company Common Stock pays a 4.43% dividend while IQVIA Holdings Inc. Common Stock pays none. Which is the better fit depends on your goals.
| IQV | WY | |
|---|---|---|
Market Cap | $42.91B | $13.67B |
Volume | 1,333,456 | 6,820,453 |
Sector | Health | Real Estate |
52-Week High | $275.02 | $27.10 |
52-Week Low | $156.66 | $18.47 |
Typical Hold Time | 6 Days | — |
Enterprise Value | $57.07B | $18.59B |
Dividend Yield | — | 4.43% |
Signals from Pluang's Aura AI — not financial advice
IQVIA Holdings (IQV) trades at $260.71, down 0.57% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $284.64. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $3.15 surpassing the $3.03 estimate. Revenue growth is steady, projected at $17.0B for 2026, while profitability metrics like a 23.01% ROE and 8.1% net income margin reflect operational strength. The company continues to innovate, launching new predictive analytics tools for life sciences clients.
The outlook for IQV remains positive, supported by strong earnings performance and analyst optimism, though investors should note valuation multiples above sector averages and debt levels. Key risks include competitive pressures in clinical research services and macroeconomic sensitivity affecting client spending.
Weyerhaeuser (WY) trades at $18.97, up 0.16% with neutral technical signals. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, while fundamentals reveal modest profitability with 6.89% net margin and 4.97% ROE. Recent news highlights institutional accumulation and upcoming Q3 earnings on October 29. The company maintains stable revenue at $6.9B but faces cash flow challenges with negative net cash flow of $203M in 2025.
Weyerhaeuser presents a mixed outlook with analyst consensus favoring bullish sentiment (52% buy ratings) and a $29.33 price target suggesting 55% upside. However, risks include weak dividend coverage, high leverage at 5x, and sensitivity to interest rates and housing market cycles. The stock's current proximity to 52-week lows offers potential value but requires careful monitoring of lumber demand recovery and Q3 earnings results.
Trailing returns across standard periods
IQVIA provides clinical research, healthcare data, technology, and consulting services to life sciences companies. Its work supports drug development and commercialization.
Read more on IQV →Weyerhaeuser Company is a timberland-focused real estate investment trust (REIT) that owns and manages more than 10 million acres of timberland in US, in addition to timberlands under long-term license in Canada. The company also manufactures wood products, including lumber, oriented strand board, and engineered wood.
Read more on WY →